



**PHARMACY AND THERAPEUTICS COMMITTEE
ACA/Exchange MEETING MINUTES
November 7, 2024**

*Attendance: Microsoft Teams Meeting
Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Kevin Caputo, Magellan Health; Edgar Chou, Jefferson Health; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; George E. Downs, Dean Emeritus and Professor, St. Joseph’s University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson; Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Student Intern; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Resident; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Lisa Murray, Staff/Clinical Pharmacist; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sydney Rosenthal, Pharmacy Student Intern; Sara Sadiq, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Sajida Sikunder, Pharmacy Student Intern; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Pharmacy Resident; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Jessica Tran, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist*

Excused: Justin Bittner, Medical Director; Connie Chan, Staff/Clinical Pharmacist; Jerry Crawford, Staff/Clinical Pharmacist; Demian Elder, Medical Director; Oluwatoyin Fadeyibi, Community Behavior Health; Sanjiv Raj, Associate VP Customer Engagement; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Minutes Review/Approval	<i>D. Dolores presented the minutes from the August 2024 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>
Policies and Procedures	<i>D. Dolores presented the policies and procedures for annual review</i> <ul style="list-style-type: none"> • <i>Pharmacy Prior Authorization</i> • <i>Pharmacy Operations and Responsibilities</i> 		<i>D. Dolores</i>	<i>Informational</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • Pharmacy Formulary Management • HPP Pharmacy Vendor Management • Pharmacy and Therapeutics (P&T) Committee • Drug Utilization Review 			
Open enrollment 11/1/2024 through 12/15/2024	<i>D. Dolores presented the open enrollment dates</i>		<i>D. Dolores</i>	<i>Informational</i>

II. Prior Authorization Updates

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Prior Authorization Criteria Review	<p><i>The Committee reviewed the Prior Authorization Criteria. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> • Analgesics Opioid Long-Acting • Analgesics Opioid Short-Acting • Bexarotene Gel • Cayston • Cystaran • Doptelet • Dupixent • Early Refills • Evrysdi • Fasenra • Lanreotide Extended Release • Ledipasvir-velpatasvir and Harvoni • Mavyret • Miglustat • Non-Formulary Exception • Nurtec • Pegasys • Pulmozyme • Quantity Limit Exceptions • Rezdiffra • Sapropterin Dihydrochloride • Sivextro • Sofosbuvir-velpatasvir and Epclusa • Sovaldi • Stelara • Taltz • Tolvaptan 	<i>The Committee approved as presented. The Prior Authorization Criteria will be sent to PARP for approval.</i>	<i>F. Vaisberg</i> <i>S. Ford</i> <i>M. Smikovecus</i> <i>S. Sadiq</i> <i>S. Staffa</i> <i>S. Jackson</i> <i>Y. Hedrick</i> <i>R. Spencer</i> <i>R. John</i>	<i>Resolved</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • <i>Ubrelvy (new for 2025)</i> • <i>Vosevi</i> • <i>Xyrem/Xywav</i> • <i>Zepatier</i> 			

III. 2024 Drug Formulary Review/Update

<p>2024 Formulary Additions</p>	<p><i>The Committee reviewed and approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Capvaxive 0.5 mL soln prsyr - T0</i> • <i>Dasatinib 100 mg tab - T5, PA</i> • <i>Dasatinib 140 mg tab - T5, PA</i> • <i>Dasatinib 20 mg tab - T5, PA</i> • <i>Dasatinib 50 mg tab - T5, PA</i> • <i>Dasatinib 70 mg tab - T5, PA</i> • <i>Dasatinib 80 mg tab - T5, PA</i> • <i>Femlyv 1-0.02 mg tab disp- T0</i> • <i>Freestyle Libre 2 Plus sensor - T3, PA, QL 2/30</i> • <i>Gallifrey 5 mg tab - T2</i> • <i>Hydrocortisone sod suc (PF) 100 mg recon soln - T4</i> • <i>Ingrezza 40 mg sprinkle cap - T5, PA, QL 30/30</i> • <i>Ingrezza 60 mg sprinkle cap - T5, PA, QL 30/30</i> • <i>Ingrezza 80 mg sprinkle cap - T5, PA, QL 30/30</i> • <i>Lofexidine hcl 0.18 mg tab- T4, PA, MDD = 16 (PA removed for 2025)</i> • <i>Mirabegron 25 mg tab ER 24h - T2, QL 30/30</i> • <i>Mirabegron 50 mg tab ER 24h - T2, QL 30/30</i> • <i>Mresvia 50 mcg/0.5 mL susp prsyr - T0</i> • <i>Novavax Covid-19 vaccine 5 mcg/0.5 mL susp prsyr - T0</i> • <i>Retevmo 120 mg tablet - T5, PA</i> • <i>Retevmo 160 mg tablet - T5, PA</i> • <i>Retevmo 40 mg tablet - T5, PA</i> • <i>Retevmo 80 mg tablet - T5, PA</i> • <i>Tremfya 200 mg/2 mL autoinjector - T5, PA</i> • <i>Tremfya 200 mg/2 mL syringe - T5, PA</i> • <i>Truqap 160 mg tab thpk - T5, PA</i> • <i>Truqap 200 mg tab thpk - T5, PA</i> • <i>Wixela Inhub 100-50 mcg/act aer pow ba - T2, QL 60/30</i> • <i>Wixela Inhub 250-50 mcg/act aer pow ba - T2, QL</i> 	<p><i>The Committee reviewed and approved as presented.</i></p>	<p><i>F. Vaisberg</i></p>	<p><i>Resolved</i></p>
--	---	---	---------------------------	------------------------

	<p>60/30</p> <ul style="list-style-type: none"> • <i>Wixela Inhub 500-50 mcg/act aer pow ba - T2, QL</i> 60/30 			
IV. New Drug Review	<p><i>(Presented in New Drug Review for Medicaid.) The following new products were reviewed and will be kept as non-formulary:</i></p> <ul style="list-style-type: none"> • <i>Vyloy (zolbetuximab-clzb) Injection</i> • <i>Vyalev (foscarbidopa and foslevodopa) Injection - formerly ABBV-951</i> • <i>Hympavzi (marstacimab-hncq) Injection</i> • <i>Itovebi (inavolisib) Tablets</i> • <i>Imuldosa (ustekinumab-srlf) Injection</i> • <i>Flyrcado (flurpiridaz F 18) Injection</i> • <i>Otulfi (ustekinumab-aauz) Injection</i> • <i>Cobenfy (xanomeline and trospium chloride) Capsules</i> • <i>Aqneursa (levacetylleucine) Granules for Oral Suspension</i> • <i>Miplyffa (arimoclomol) Capsules</i> • <i>Ebglyss (lebrikizumab-lbkz) Injection</i> • <i>Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Injection</i> • <i>Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Injection</i> • <i>Boruzu (bortezomib) Injection</i> • <i>Pavblu (afibercept-ayyh) Injection</i> • <i>Lazcluze (lazertinib) Tablets</i> • <i>Niktimvo (axatilimab-csfr) Injection</i> • <i>Livdelzi (seladelpar) Capsules</i> 	<i>The Committee approved the New Drug Review as presented and recommended</i>	<i>R. John</i>	<i>Resolved</i>

VII. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held February 2025.



12/17/2024

Danielle Dolores, Director of Pharmacy Services

Date